Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine
Spyros Chalkias, Frank Eder, Brandon Essink, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 20

Showing 20 citing articles:

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Young‐Jun Park, Dora Pinto, Alexandra C. Walls, et al.
Science (2022) Vol. 378, Iss. 6620, pp. 619-627
Open Access | Times Cited: 199
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Young‐Jun Park, Dora Pinto, Alexandra C. Walls, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 38
SARS-CoV-2 Omicron boosting induces de novo B cell response in humans
Wafaa B. Alsoussi, Sameer Kumar Malladi, Julian Q. Zhou, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 29
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant
Suzanne M. Scheaffer, Diana Lee, Bradley Whitener, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 26
A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains
Zhiren Zhang, Qiaren He, Wei Zhao, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 14, pp. 4164-4164
Open Access | Times Cited: 23
Predicting the efficacy of variant-modified COVID-19 vaccine boosters
David S. Khoury, Steffen S. Docken, Kanta Subbarao, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 23
A Bivalent Omicron-containing Booster Vaccine Against Covid-19
Spyros Chalkias, Charles Harper, Keith Vrbicky, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 22
Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection
Marcel E. Curlin, Timothy A. Bates, Gaelen Guzman, et al.
Med (2022) Vol. 3, Iss. 12, pp. 827-837.e3
Open Access | Times Cited: 19
A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses
Joseph Torresi, Melissa A. Edeling, Terry Nolan, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 16
Novel coronavirus mutations: Vaccine development and challenges
Wan-Rong Luo, Xiaomin Wu, Wei Wang, et al.
Microbial Pathogenesis (2022) Vol. 173, pp. 105828-105828
Open Access | Times Cited: 13
Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants
Rui Wang, Xun Huang, Tian-Shu Cao, et al.
Virology (2022) Vol. 576, pp. 61-68
Open Access | Times Cited: 10
The potential clinical impact of implementing different COVID-19 boosters in fall 2022 in the United States
Michele Kohli, Michael Maschio, Amy S. Lee, et al.
Journal of Medical Economics (2022) Vol. 25, Iss. 1, pp. 1127-1139
Open Access | Times Cited: 10
Protecting Children Against Omicron
Sophie E. Katz, Kathryn M. Edwards
JAMA (2022) Vol. 327, Iss. 22, pp. 2195-2195
Open Access | Times Cited: 8
Monovalent and trivalent VSV-based COVID-19 vaccines elicit neutralizing antibodies and CD8+ T cells against SARS-CoV-2 variants
Kate A. Parham, Gyoung Nyoun Kim, Connor G. Richer, et al.
iScience (2023) Vol. 26, Iss. 4, pp. 106292-106292
Open Access | Times Cited: 3
Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline
Daniele Focosi, Fabrizio Maggi
Viruses (2022) Vol. 14, Iss. 11, pp. 2488-2488
Open Access | Times Cited: 5
Emergence of the SARS-CoV-2 Omicron Variant: Current Treatments and Vaccines for COVID-19
Valerie Vidian, Dikson, Vivian Litanto, et al.
Exploratory Research and Hypothesis in Medicine (2022) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 2
Monovalent and trivalent VSV-based COVID-19 vaccines elicit potent neutralizing antibodies and immunodominant CD8+ T cells against diverse SARS-CoV-2 variants
Kate A. Parham, Gyoung Nyoun Kim, Nasrin Saeedian, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine
Georgia Deliyannis, Nicholas A. Gherardin, Chinn Yi Wong, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
A novel SARS-CoV-2 Beta RBD DNA vaccine directly targeted to antigen-presenting cells induces strong humoral and T cell responses
Katarzyna Kuczkowska, Louise Bjerkan, Elisabeth Stubsrud, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access
Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent Vaccines
Evan J. Anderson, Lisa A. Jackson, Nadine Rouphael, et al.
Research Square (Research Square) (2022)
Open Access
Page 1

Scroll to top